CHF Solutions Initiatives at HFSA 24th Annual Scientific Meeting Highlight Aquadex Therapy Performance in Heart Failure
September 30 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced its initiatives for the 24th Annual Scientific Meeting of
the Heart Failure Society of America (HFSA) from September 30 to
October 6, 2020. The conference is being held this year on a
virtual platform at
https://hfsa.org/annualscientificmeeting/program.
Key highlights on Aquadex™ Therapy at VirtualHFSA2020
include:
- Clinical Study Data
from “Ten Year Experience of Ultrafiltration for Management of
Acute Decompensated Heart Failure (ADHF)” presented during the Live
Poster Chats on Saturday, October 3 and Sunday, October 4 from 1:15
to 2:45pm ET.
- Case Study on
“Outpatient Ultrafiltration to prevent Hospital Readmission During
COVID-19 Pandemic in Diuretic Intolerant Patient: Case Study”
presented during the Live Poster Chats on Saturday, October 3 and
Sunday, October 4 from 1:15 to 2:45pm ET.
- Virtual booth at
https://virtual.hfsa.org/node/301597/exhibithall/0/422944#lct=exhibithall-422944
with an opportunity to ask questions of CHF Solutions’ clinical
specialists and access educational materials regarding the
treatment of heart failure patients, including the recent webinar
“Precision Medicine for the Treatment of Fluid Overload in Patients
with Acute Heart Failure” presented by Dr. John Jefferies, the Jay
M. Sullivan Distinguished Chair in Cardiovascular Medicine and
Chief of Cardiology at the University of Tennessee Health Science
Center.
“This year’s virtual platform provides medical professionals
with efficient access to valuable information and clinical data. We
are excited to share how the Aquadex system has proven to be
advantageous in the delivery of effective care for heart failure
patients and patients with COVID-19,” said John Erb, Chairman and
CEO of CHF Solutions. “We look forward to the presentation of
additional data involving the use of ultrafiltration in the
treatment of heart failure during the conference.”
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device company dedicated
to changing the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The company is
focused on developing, manufacturing and commercializing the
Aquadex SmartFlow™ system for ultrafiltration therapy. CHF
Solutions is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy
using a simple, flexible and smart method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The
Aquadex SmartFlow system is indicated for temporary (up to 8 hours)
or extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the company’s initiatives in
connection with the 24th Annual Scientific Meeting of the Heart
Failure Society of America. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our expectations regarding
the potential impacts of the COVID-19 pandemic on our business
operations, our ability to execute on our commercial strategy, the
possibility that we may be unable to raise sufficient funds
necessary for our anticipated operations, our post-market clinical
data collection activities, benefits of our products to patients,
our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. CHF Solutions does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024